Sanofi–Translate Bio COVID-19 vaccine

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Retrieved on: 
Monday, November 20, 2023

WATERTOWN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Owen Hughes to its board of directors.

Key Points: 
  • WATERTOWN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Owen Hughes to its board of directors.
  • Mr. Hughes is an accomplished life sciences executive with nearly three decades of experience in investing, operations and corporate governance.
  • “We are thrilled to welcome Owen to the board of directors and leverage his experience across capital markets and pivotal business development opportunities,” said Bruce Downey, chairman of the board of directors of C4 Therapeutics.
  • “I look forward to working with the board of directors and management team to capitalize on the company’s scientific prowess to the benefit of patients and shareholders alike.”

Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

Retrieved on: 
Wednesday, August 2, 2023

and Dolca Thomas, M.D.

Key Points: 
  • and Dolca Thomas, M.D.
  • to the Allakos board of directors.
  • Dr. Sutherland was the Chief Executive Officer of Seeker Biologics, a privately-held company, and currently serves on the board of directors of Krystal Biotech, Inc. and Vanqua Bio, Inc.
  • Dr. Thomas is a Venture Partner with Samsara BioCapital and currently serves on the board of directors of Chinook Therapeutics, Inc. and Ventus Therapeutics, Inc.

Azitra Adds Biotech Leaders Barbara Ryan and John Schroer to Its Board of Directors

Retrieved on: 
Wednesday, July 19, 2023

BRANFORD, Conn., July 19, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the addition of two members to its board of directors, Barbara Ryan and John Schroer.

Key Points: 
  • BRANFORD, Conn., July 19, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the addition of two members to its board of directors, Barbara Ryan and John Schroer.
  • "We are thrilled to further strengthen the Azitra team by welcoming Barbara and John to our board and by leveraging their wealth of knowledge in biotech, corporate strategy, and capital markets," said Francisco Salva, President and CEO of Azitra.
  • "Both Barbara and John are widely recognized leaders in biotech, and their additions to Azitra's board will be invaluable as we grow the company to support clinical trials and our partnership with Bayer."
  • Barbara Ryan is a Board Member of Indivior PLC and MiNK Therapeutics, the CEO of Barbara Ryan Advisors, and a Senior Advisor at Ernst & Young.

Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 3, 2023

ET

Key Points: 
  • ET
    CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Ron Renaud as president and chief executive officer (CEO), and member of the company’s board of directors, effective June 12, 2023.
  • Mr. Renaud will succeed Tony Coles, M.D., the current CEO and chairperson of the board of directors, who will continue in his role as chairperson.
  • The company also reported financial results for the first quarter ended March 31, 2023 and provided key pipeline and business updates.
  • Mr. Renaud brings more than 25 years of experience in evaluating, building, and leading biotechnology companies, with deep expertise in executive leadership, finance, and operations.

New Executive Leadership Team Appointed to Accelerate XOMA’s Differentiated Royalty Monetization Strategy

Retrieved on: 
Wednesday, January 4, 2023

EMERYVILLE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Jim Neal has retired as Chief Executive Officer and two finance and biotechnology industry veterans have joined in newly created executive leadership roles to drive the Company’s next phase of accelerated growth.  Mr. Neal has resigned as a director of the company effective January 1, 2023.  The Board of Directors has appointed Owen Hughes as Executive Chairman of the Board and Brad Sitko as XOMA’s Chief Investment Officer.

Key Points: 
  • The Board of Directors has appointed Owen Hughes as Executive Chairman of the Board and Brad Sitko as XOMA’s Chief Investment Officer.
  • “The Board recognized XOMA’s growth would be best served with a leadership structure that reflects the unique demands of the Company’s royalty aggregator strategy.
  • The Board is fully committed to supporting their efforts as they accelerate the expansion of XOMA’s royalty portfolio,” stated W. Denman (Denny) Van Ness, Lead Independent Director of XOMA.
  • Mr. Sitko brings deep expertise in royalty monetizations having been involved with the asset class for over 15 years as an investor, investment banker, and strategy consultant.

Ikena Oncology Appoints Owen Hughes as Board Chair

Retrieved on: 
Monday, December 19, 2022

BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that after a successful 4-year tenure as Chairman of the Board of Directors, Ron Renaud will be stepping down from the role to focus on his new position as Managing Director at Bain Capital Life Sciences. Owen Hughes has been appointed as a new board member and will be assuming the role of Chair of the Board of Directors, effective December 15, 2022.

Key Points: 
  • Owen Hughes has been appointed as a new board member and will be assuming the role of Chair of the Board of Directors, effective December 15, 2022.
  • “On behalf of the Board of Directors and the entire company, I am thrilled to welcome Owen to our board.
  • Owen is a perfect addition to the board and his experience and values will continue to support Ikena’s trajectory.”
    Hughes, who serves as Chief Executive Officer of Sail Bio and Co-Founder of Cullinan Oncology, will join as Chairman of the Board of Directors.
  • “I am looking forward to working together to advance and grow Ikena’s pipeline and redefine the targeted oncology landscape.”

Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer

Retrieved on: 
Tuesday, September 20, 2022

CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced the promotion of Phillip Samayoa, Ph.D., to chief strategy officer.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced the promotion of Phillip Samayoa, Ph.D., to chief strategy officer.
  • Dr. Samayoa has led strategy, corporate and portfolio development at Generation Bio since he joined the company in 2017, most recently serving as senior vice president.
  • Phillip has been instrumental in building a holistic strategy for platform development that will enable its application to multiple genetic medicine modalities, said Geoff McDonough, M.D., president and chief executive officer of Generation Bio.
  • In this new role Phillip will lead corporate strategy, business development and discovery research, enabling the integration of these key strategic activities.

Odylia Therapeutics Announces Appointment of Two New Members to Board of Directors

Retrieved on: 
Thursday, August 18, 2022

Dr. Walker joins the Board from Sanofi, where she serves as Senior Counsel, Vaccines Patents.

Key Points: 
  • Dr. Walker joins the Board from Sanofi, where she serves as Senior Counsel, Vaccines Patents.
  • She has more than 15 years of experience in intellectual property and other legal matters in the healthcare sector.
  • Odylia is a nonprofit biotech focused on bringing life-altering and lifesaving treatments to those with rare diseases.
  • We partner with the patient community, researchers, clinicians, and financial donors to bring promising therapeutics to clinical trials.

SalioGen Therapeutics Strengthens its Leadership Team to Advance its Gene Coding™ Platform

Retrieved on: 
Wednesday, July 20, 2022

We look forward to benefitting from their leadership as they help to maximize the potential impact of Gene Coding not only on the genetic medicines industry, but on patients around the world.

Key Points: 
  • We look forward to benefitting from their leadership as they help to maximize the potential impact of Gene Coding not only on the genetic medicines industry, but on patients around the world.
  • She also served as the acting Chief Medical Officer at clinical-stage gene therapy company Solid Biosciences.
  • Joe Senn, Ph.D. has experience with nearly all therapeutic modalities, including small molecules, biologics, antisense, gene editing and mRNA therapeutics.
  • SalioGen Therapeutics has launched Gene CodingTM, a genetic medicine platform, to develop durable, broadly applicable genetic medicines, using its Exact DNA Integration TechnologyTM (EDITTM) platform.

Alumis Expands Industry-Leading Leadership Team With Appointments of Sara Klein as General Counsel and Secretary and John R. Schroer as Chief Financial Officer

Retrieved on: 
Wednesday, April 6, 2022

Alumis, a precision immunology company incubated by Foresite Labs that is reimagining the discovery, development and treatment of autoimmune disorders, today announced the appointments of Sara Klein as general counsel and secretary and John R. Schroer as chief financial officer.

Key Points: 
  • Alumis, a precision immunology company incubated by Foresite Labs that is reimagining the discovery, development and treatment of autoimmune disorders, today announced the appointments of Sara Klein as general counsel and secretary and John R. Schroer as chief financial officer.
  • John R. Schroer joins Alumis from ArsenalBio where he served as chief financial officer.
  • Prior to that role, Mr. Schroer served as chief financial officer and treasurer at Translate Bio.
  • From 2009 to December 2013, he served as president and chief investment officer at Schroer Capital, LP, a financial services company that he founded.